Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 7, 2023

A Systematic Review of the Synergy of Traditional Chinese Medicine and Western Medicine in the Treatment of Heart Failure in Dilated Cardiomyopathy

Download as PDF

DOI: 10.23977/medsc.2023.040720 | Downloads: 7 | Views: 254

Author(s)

Dan Qi 1,2, Huan Liu 2, Fangyuan Wang 2, Liangyu Cui 1,2, Yuying Qi 2, Zhou Qian 2, Jing Ma 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Department of Traditional Chinese Medicine, Xijing Hospital of Air Force Medical University, Xi'an, Shaanxi, 710032, China

Corresponding Author

Huan Liu

ABSTRACT

In order to analyse the TCM treatment, TCM medication, clinical efficacy and safety of TCM synergy in the treatment of dilated cardiomyopathy heart failure, we used method of data mining was used to systematically evaluate. We searched CNKI, WanFang, VIP, Sinomad, Web of Science, Pubmed and other databases, and performed meta-analysis or descriptive analysis on clinical efficacy and LFE, LVEDD, LVESD and serum NT-ProBNP from the establishment of each database to July 2021. For the literature that meets the inclusion criteria, a database was established by selecting Chinese medicine prescriptions, and frequency statistics, association rule analysis and other methods were used to analyze Chinese medicine treatment methods, commonly used Chinese medicines and drug pairs or drug groups. Resultly, a preliminary search of 858 articles resulted in the inclusion of 20 RCTs with 1745 patients. There were 9 kinds of treatment methods involved, and the most frequently used were 29.23% for qi invigoration, 24.62% for blood revitalization, and 18.60% for water conservancy. 48 flavors of commonly used Chinese medicine, the frequency of use is 90% of astragalus, 75% of danshen and 65% of ginseng. There were 30 commonly used drug pairs or drug groups, and the high-frequency drug pairs included astragalus + danshen, laurel branch + astragalus, danshen + laurel branch, etc., and the frequency of use was 43.3%, 36.7%, 36.7%, etc. The TCM synergistic treatment group was better than the Western drug control in terms of total clinical effective rate, LFE, LVEDD, LVESD and serum NT-ProBNP. In conclusion, the main treatment methods of heart failure in dilated cardiomyopathy are qi invigoration, blood revitalization and water rejuvenation, commonly used Chinese medicines are astragalus, danshen, ginseng, etc., commonly used high-frequency drugs are astragalus + danshen, guizhi + astragalus, danshen + guizhi, etc. And the synergistic treatment of traditional Chinese and Western medicine is obviously better than that of western medicine alone.

KEYWORDS

Dilated cardiomyopathy; Heart failure; Data mining; Medication rules; Meta-analysis

CITE THIS PAPER

Dan Qi, Huan Liu, Fangyuan Wang, Liangyu Cui, Yuying Qi, Zhou Qian, Jing Ma, A Systematic Review of the Synergy of Traditional Chinese Medicine and Western Medicine in the Treatment of Heart Failure in Dilated Cardiomyopathy. MEDS Clinical Medicine (2023) Vol. 4: 128-136. DOI: http://dx.doi.org/10.23977/medsc.2023.040720.

REFERENCES

[1] McKenna W J, Maron B J, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies[J]. Circ Res, 2017, 121(7): 722-730. 
[2] Cardiovascular Disease Branch of Chinese Medical Association, Chinese Myocarditis Cardiomyopathy Collaborative Group. Guidelines for the diagnosis and treatment of dilated cardiomyopathy in China[J]. Journal of Clinical Cardiology, 2018, 34(05): 421-434. 
[3] Merlo M, Cannata A, Gobbo M, et al. Evolving concepts in dilated cardiomyopathy[J]. Eur J Heart Fail, 2018, 20(2): 228-239. 
[4] Ponikowski P, Anker S D, AlHabib K F, et al. Heart failure: preventing disease and death worldwide[J]. ESC Heart Fail, 2014, 1(1): 4-25. 
[5] Tan Yuqing. Retrospective analysis and miRNA regulation mechanism of dilated cardiomyopathy by warm yangqi and blood activation[D]. Beijing University of ChineseMedicine, 2021. 
[6] Lu Ping, Wang Yisheng, Huang Haiyan. Efficacy and safety observation of Qi with warm yang decoction combined with Western medicine in the treatment of dilated cardiomyopathy [J]. Sichuan Journal of Traditional Chinese Medicine, 2019, 37(12):65-67. 
[7] Han Bing. Clinical efficacy of Qianqiang Qiangxin capsules in the treatment of heart failure with dilated cardiomyopathy in 30 cases[J]. World Latest Medical Information Abstract, 2016, 16(61):205+207. 
[8] Li Weiji, Liu Huan. Clinical efficacy and mechanism of Tongxinluo capsules in the treatment of dilated cardiomyopathy [J]. Journal of Hubei University of Chinese Medicine, 2021, 23(01):71-74. 
[9] Cardiovascular Branch of the Chinese Medical Association, Editorial Committee of the Chinese Journal of Cardiovascular Disease, Working Group on Diagnosis and Treatment Recommendations for Cardiomyopathy in China. Suggestions for diagnosis and treatment of cardiomyopathy[J]. Chinese Journal of Cardiology, 2007, 35(01):5-16. 
[10] Wang Hua, Liang Yanchun. Chinese guidelines for the diagnosis and treatment of heart failure 2018[J]. Chinese Journal of Cardiology, 2018, 46(10):760-789. 
[11] Gao Qun, Li Sinei, Lin Qian. Effects of Astragalus and Codonopsis on Calcium Transients of Cardiomyocytes in Mice with Heart Failure[J]. Journal of Traditional Chinese Medicine, 2017, 58(16): 1408-1411. 
[12] Sui Y, Zhang K, Ren Y, et al. The role of Nrf2 in astragaloside IV-mediated antioxidative protection on heart failure [J]. Pharmaceutical Biology, 2020, 58(1): 1201-1207. 
[13] Chen P, Xie Y, Shen E, et al. Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy[J]. European Journal of Pharmacology, 2011, 658(2-3): 168-174. 
[14] Wang X, Guo D, Li W, et al. Danshen (Salvia miltiorrhiza ) restricts MD2/TLR4‐ MyD88 complex formation and signalling in acute myocardial infarction‐induced heart failure[J]. Journal of Cellular and Molecular Medicine, 2020, 24(18): 10677-10692. 
[15] Zhang X, Wang Q, Wang X, et al. Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway[J]. Biomedicine & Pharmacotherapy, 2019, 112: 108599. 
[16] Huang L, Zhu J, Zheng M, et al. Tanshinone IIA protects against subclinical lipopolysaccharide induced cardiac fibrosis in mice through inhibition of NADPH oxidase[J]. International Immunopharmacology, 2018, 60: 59-63. 
[17] Tang Yong, Sun Zhijia, Hou Le, et al. Study on improving myocardial energy metabolism in rats with chronic heart failure by invigorating qi and removing stasis[J]. World Journal of Traditional Chinese Medicine, 2019, 14(05): 1168-1172. 
[18] Zhang Yuanli. Clinical efficacy of compound danshen injection combined with astragalus in the treatment of chronic heart failure[J]. Medical Information, 2014, (23): 493.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4576
Visits: 198341

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.